MassRoots, Inc. (OTCQB:MSRT) , one of the leading publicly-traded cannabis technology companies, and Grownetics, a leader in cultivation automation and optimization for the cannabis industry, are pleased to announce they are partnering to aggregate data collected throughout the cannabis supply chain to provide reports and analysis to cannabis businesses.
“Over the past year, we have worked diligently to develop the functionality to allow cannabis consumers to review the products they purchase in dispensaries. By comparing this information with the millions of data points collected by the Grownetics system, both companies could be able to provide invaluable information at the strain level to our business clients,” stated MassRoots Chief Executive Officer Isaac Dietrich. “We believe this analysis will be some of the most comprehensive and innovative reporting ever offered about specific strains and products in the cannabis industry.”
Grownetics, which is headquartered at the Boomtown Accelerator in Boulder, CO, is developing a sophisticated automation system for cannabis cultivators and could be the future of agricultural artificial intelligence. By combining big data and machine learning optimization algorithms, the company helps growers reduce costs, decrease energy usage, and increase overall quality and yield based on strain.
“We’re extremely excited about this partnership with MassRoots. Until this point, our team has strived to developed the most effective and innovative cultivation system on the market,” added Eli Duffy, Grownetics CEO. “Partnering with MassRoots will allow us to leverage their connections and expertise to scale our technology and become the most dominant cultivation technology company in the cannabis industry.”
MassRoots announced in January that it closed an acquisition of DDDigital, Inc. d.b.a. “Whaxy,” a menu management and online ordering system for medical and adult-use dispensaries. By correlating the data collected by this system with the data collected by MassRoots’ social platform and by Grownetics, there is significant potential for meaningful analysis.
“Grownetics’ value proposition to cannabis cultivation facilities is clear — it allows them to increase yields with less resources,” continued Dietrich. “We believe the partnership creates a value-add to our offerings to businesses.”
Based on initial data with their first customer, The Flower Collective, Grownetics’ technology could provide up to a 60% reduction in operating costs. These results have been validated by the University of Colorado’s Leeds School of Business Entrepreneurial Solutions team. The technology has been used by Ph.D researchers in California to optimize indoor cultivation.
The strategic alliance with Grownetics complements the recently announced partnership between MassRoots and New Frontier Data, and could amplify the depth and extent of analysis provided to cannabis business cultivators, retailers, and consumers.
About MassRoots, Inc.
MassRoots is one of the largest technology platforms for the regulated cannabis industry. The Company’s mobile apps enable consumers to make educated cannabis purchasing decisions through community-driven reviews. MassRoots is proud to be affiliated with the leading businesses and organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. For more information, please visit MassRoots.com/Investors.
About Grownetics
Grownetics™ is a cultivation technology company which has built fully automated smart thinking garden.  By combining big data and machine learning, Grownetic’s helps growers decrease their costs, increase their plant’s yields, and save valuable resources.  In 2016, Grownetics was awarded both the Cannabist’s award for best cannabis technology startup and best technology company in the University of Colorado’s New Venture Challenge.
Forward-looking Statements
Certain matters discussed in this announcement contain statements, estimates and projections about the growth of MassRoots’ business, potential partnerships, new features, and related business strategy. Such statements, estimates and projections may constitute forward-looking statements within the meaning of the federal securities laws. Factors or events that could cause our actual results to differ may emerge from time to time. MassRoots undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The recipient of this information is cautioned not to place undue reliance on forward-looking statements.
Click here to connect with MassRoots, Inc. (OTCQB:MSRT) to receive an Investor Presentation.

Source: www.prnewswire.com

Naturally Splendid (TSXV:NSP) is pleased to announce its financial results for the first quarter ended March 31st, 2017. All amounts are in Canadian dollars and are prepared in accordance with International Financial Reporting Standards.
Naturally Splendid recorded $587,203 in revenue during the three months ended March 31, 2017. This represents a decrease compared to the first three months of 2016, when sales totaled $1,440,028. The decrease in top line revenue was mainly due to a $1 million decrease in bulk sales of hemp products to South Korea, partially offset by inclusion of the POS-BPC operations which commenced in the second quarter of 2016. The Company’s retail brands, NATERA(R), CHII(TM) and PawsitiveFX(TM) continue to make strong contributions during the period. The bulk sale market has been increasingly competitive since mid 2016 and margins continue to be very tight.
Gross margin was $151,437 during the three months ended March 31, 2017 compared to $80,353 in 2016. The Company significantly changed its sales mix in 2017 with a reduction of export bulk seed sales, which are generally sold at a lower gross margin percentage. The Company is focused on its higher margin products and new commercial opportunities, which helped the margins. Overall gross profits increased to 25.8% of sales compared to 5.6% in 2016.
Naturally Splendid CEO Dave Eto states, “While the first quarter of 2017 was challenging from a top line revenue perspective, we implemented significant changes to the overall business model, restructured management, team members and realigned the business focus while trying to increase product margins and manage expenses. A significant result of these adjustments is a notable overall increase in margins, which is very promising for shareholders. All the changes we designed in the Strategic plan for this year have been implemented so now we focus on execution. Korean bulk hemp sales have been extremely competitive and difficult to maintain versus last year, so our attention will be on four main areas; NATERA(R) CBD ( Cannabidiol ) products that are being readied for distribution in Japan: HempOmega(TM) through our partnership with Canature Processing Ltd. and new opportunities underdevelopment; NATERA(R) brand and our recently launched NATERA(R) Hemp Protein 369 product, which is also marketed through Isodiol’s IsoSport Pro369; and our Co-packing facility which is fully operational and filling orders.”
Dave Eto closes by saying, “I’m excited for the potential growth this year presents for the company, and I firmly believe Naturally Splendid is positioned to be a leader in its sector. I look forward to providing updates as business develops.”
Naturally Splendid’s unaudited condensed financial statements and management’s discussion and analysis have been filed on Naturally Splendid’s profile on the SEDAR website.
About Naturally Splendid Enterprises Ltd.
Naturally Splendid is a multifaceted biotechnology company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and non-psychoactive cannabinoid compounds in a broad spectrum of applications.
Naturally Splendid currently has six innovative divisions: (1) Natera(R) brand of retail hemp superfood products currently distributed throughout North America and Asia; (2) Chi Hemp Industries Incorporated (Chii) is selling natural and organic hemp products through e-commerce (3) PawsitiveFX(R) brand of pet care products; (4) Natera(R)Ingredients, division of plant-derived bulk ingredients including patent-pending HempOmega(TM); (5) POS-BPC Facility a 12,000-square-foot facility which is managed for Naturally Splendid by POS Bio-Sciences – is positioned to offer commercial-scale custom processing solutions for biological materials, such as functional foods and natural health ingredients to a wide range of clients;(6) Naturally Splendid USA offers ,Natera(R)CBD brand of retail hemp based cannabinoid nutraceutical and cosmeceutical products and Natera(R)Skincare brand of retail hemp based cosmeceutical products. Naturally Splendid`s advanced technologies, industry expertise, and strategic partners allow for the creation of customized solutions with a consistent focus on quality and sustainability.
 
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, the Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Click here to connect with Naturally Splendid (TSXV:NSP) to receive an Investor Presentation.

Source: www.thenewswire.com


Alliance Growers Corp. (CSE:ACG; FWB:1LA) provided an update on the milestones achieved. The company continues to execute on its business plan to develop its business strategy that differentiates Alliance Growers from other Canadian cannabis companies. The company is advancing on several key fronts.
CannaApp
The CannaApp announced in a news release on Feb. 16, 2017, is under development and is expected to be in beta testing in the coming months. CannaApp will provide a means for licensed growers and dispensaries to advertise products, facilitating sales and deliveries between licensed growers, dispensaries and customers, as well as aggregating social interactions. The marketplace will be also be user content driven, allowing it to expand rapidly to meet market demands. The marketplace will be a full-service solution to sourcing, variety, selection, sales and delivery.
The CannaApp will be a valuable tool for anybody involved in the cannabis industry, from growers to end-users and all points in between. This would include providers of equipment for growing and extraction, plant nutrients, product packaging, and other service providers in the industry.
The CannaApp will position itself to be the eBay and Amazon of medical and recreational marijuana sales. Due to its user-driven model, the business will be able to expand into the national and international markets, wherever legally available. The CannaApp will also provide unique access to potential customers looking for services that are provided by the cannabis botany centre.
Alumina Partners equity facility financing
On April 6, 2017, Alliance Growers announced that the company had executed on the term sheet for a financing commitment offered by Alumina Partners LLC, a New York-based private equity firm, for a $5-million equity facility in a series of private placements, with an option to extend the commitment up to $10-million.
The company is closing the first tranche this week of the offering by issuing one million units at an issuance price of 10.5 cents per unit for $105,000, representing a portion of the commitment fee in respect of the equity facility. Each unit consists of one common share and one share purchase warrant, exercisable at 21 cents per share for a period of two years. Alliance Growers expects to close larger placements with Alumina Partners at progressively higher prices.
Cannabis botany centre (BRIM)
BRIM will be issued the first tranche of shares in Alliance Growers this week. The development of BRIM, together with additional partnerships and investments, is designed to provide Alliance Growers with the ability to produce revenue from the sale of cannabis and other plantlets under contract, generate revenue from the processing and resale of cannabidiol (CBD) oil in Canada, the United States and offshore, provide cold storage facilities utilizing the one-of-a-kind cryotissue cold storage technology for tissue culture preservation and regeneration as needed on long-term basis, and provide extraction services as retail services for cultivators and create custom profiles for extraction for botanicals oils for the retail market.
Investment in Canwe
Alliance Growers is moving ahead with a strategic investment in Canwe Growers Inc. as part of the company’s business plan of securing long-term plantlet sale contracts for the cannabis botany centre and offtake agreements at wholesale cost for flower to be acquired by Alliance Growers for CBD oil extraction.
On Feb. 21, 2017, Alliance Growers announced the closing of the first tranche of instalment of its subscription for common shares in New Maple Holdings Ltd., the parent company of Canwe. Canwe is an Ontario-based company preparing to apply for a producer’s licence under the access to cannabis for medical purposes regulations (the ACMPR). Canwe has access to a 22-acre property 1.5 hours northwest of Toronto, where it plans to build a facility focused on producing clean, premium-quality cannabis. Canwe has amassed a stellar team which includes licensed producer MedReleaf Corp.’s former head grower and his No. 2 aide, both of whom are expert cannabis growers who intimately know the cannabis cultivation cycle from seed to sale. With Alliance Growers’ four-pillar strategy and Canwe’s experienced team, the two companies plan to work together to form business synergies with the goal of creating a strong presence in Canada’s fast-growing medical cannabis space.
In conjunction with the investment, New Maple and Alliance Growers intend to have a business arrangement for the purchase and sale between the parties of live cannabis plants, tissue culture plantlets, and other cannabis products and services.
Joint venture with Israeli medical cannabis company
Alliance Growers is structuring terms for financing an investment in an Israeli medical cannabis company for a significant equity investment which will lead to a significant portion of its high-grade CBD production.
Included in the discussions is the joint development of land for the growth of high-quality cannabis plants, as legally permitted in an offshore, low-operating-cost jurisdiction. This would facilitate the importation of the CBD oil into various states in the United States, into Canada when legalized and into other countries as permitted.
This joint venture and other similar partnerships are what will make Alliance Growers stand out from other Canadian cannabis companies that are directly affected by Health Canada rules and regulations. Alliance Growers plans to produce and sell more CBD oil from outside Canada.
Click here to connect with Alliance Growers Corp. (CSE:ACG; FWB:1LA) to receive an Investor Presentation.

Source: www.alliancegrowers.com


MassRoots, Inc. (OTCQB:MSRT), a leading technology platform for medical cannabis patients and businesses, is pleased to announce it has launched an activist celebrity influencer campaign to help accelerate its user growth. One of the world’s most renowned cannabis consumers, Snoop Dogg (Snoop), has started to drive his 17 million Instagram fans and followers to join the MassRoots platform as one of the first influencers in the program.
“As we scale our user base towards two million users, we’re looking to leverage the following and influence of pro-cannabis celebrities to help break MassRoots into the mainstream,” said MassRoots Chief Executive Officer Isaac Dietrich. “Snoop’s extensive following can undoubtedly help take MassRoots and the legalization movement to the next level as we look to expand our market share in the rapidly growing cannabis industry.”
“Check out MassRoots in the App Store, the community just for cannabis,” says Snoop. “They’re doing big things to help spread marijuana legalization.”
About MassRoots
MassRoots is one of the largest technology platforms for the regulated cannabis industry. The Company’s mobile apps enable consumers to make educated cannabis purchasing decisions through community-driven reviews. MassRoots is proud to be affiliated with the leading businesses and organizations in the cannabis industry, including the ArcView Group and National Cannabis Industry Association. For more information, please visit MassRoots.com/Investors.
Forward-looking Statements
Certain matters discussed in this announcement contain statements, estimates and projections about the growth of MassRoots’ business, potential partnerships, new features, and related business strategy. Such statements, estimates and projections may constitute forward-looking statements within the meaning of the federal securities laws. Factors or events that could cause our actual results to differ may emerge from time to time. MassRoots undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The recipient of this information is cautioned not to place undue reliance on forward-looking statements.
Click here to connect with MassRoots, Inc. (OTCQB:MSRT) to receive an Investor Presentation.

Source: www.prnewswire.com

Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces plans for research and formulation development (“R&D”) on nonsteroidal anti-inflammatory drugs (“NSAIDs”) utilizing its patented technology and as provisioned within its previously announced 2017 & 2018 R&D program.
Lexaria will conduct in vitro absorption studies utilizing the Company’s technology to examine improvements in absorption across human intestinal tissue, which is expected to be followed by in vivo (animal) studies to confirm the Company’s hypothesis regarding first-pass liver metabolism. The Company postulates that its technology may enable oral delivery of NSAIDs without encountering first-pass liver metabolism, which has the potential to greatly reduce corresponding liver damage.
Pain-relief drugs are comprised mostly of NSAIDs and of opioids and represented a $36.6 billion market in 2014. (MSP, BCC Research – The Global Market for Pain Management Drugs and Devices, September 2015) Long term use or overuse of NSAID’s has been associated with chronic liver conditions that can be debilitating and even cause death.
Common generic forms of NSAIDS are products such as Aspirin, Ibuprofen, Naproxen, Diclofenac and others. Acetaminophen is sometimes included within this list. More effective absorption of NSAIDS may also lead to more effective pain killing properties, thus allowing for fewer opioid medication prescriptions. Prescription based opioid medications are responsible for nearly 18,000 deaths annually in the USA. (National Institute of Health)
Lexaria has a total of 18 patents pending — including the delivery of NSAIDs — and patent applications filed in more than 40 countries worldwide.
Separately, Lexaria also announces it has received US$34,753.40 from the exercise of warrants previously granted. The stock warrants were exercised at prices of US$0.2273 and US$0.1818, for a total of 156,750 common shares being issued. All warrants are being exercised by third parties who are neither officers nor directors of the Company.
No commissions or placement fees have been paid related to the funds received from this warrant exercise. Proceeds will be used for general corporate purposes. Lexaria extends its thanks to its loyal shareholders for their continued support.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Lexaria
Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

Keep reading... Show less

Harvest One Cannabis Inc. (TSXV:HVT) through its wholly owned Swiss subsidiary, Satipharm AG (“Satipharm“), is pleased to announce that the first shipment of Satipharm’s Gelpell CBD capsules has been received by the Company’s distribution partner HL Pharma in Australia and is ready for distribution, making the capsules one of the first medicinal cannabis products available to approved prescribers in the country.
The proprietary gastro-resitant microgel capsules are able to be used in the treatment of a variety of medical conditions as approved by prescribing physicians under Australian Federal and State legislation.
Satipharm Gelpell CBD Capsules – Product Overview
Satipharm’s Gelpell CBD capsules have successfully undergone a Phase 1 Clinical Trial for safety and bioavailability and are produced under Good Manufacturing Practices (GMP) in Switzerland. The capsules’ active ingredient, cannabidiol (CBD), is derived from medical cannabis grown under Good Agricultural and Collection Practices (GACP) in controlled environments. For the Australian market, the capsules are currently available in a 10mg and a 50mg CBD presentation and contain no detectable levels of Tetrahydrocannabinol (THC). Other formulations that include THC are in development and will be introduced to the market in the near future.
“Bringing Satipharm’s sophisticated products to international medical cannabis markets as legislations open up is an integral part of the Company’s agressive growth strategy,” says Andreas Gedeon, Harvest One’s Chief Executive Officer. “The arrival of our capsules in Australia is great news for medical cannabis patients in the country. It also further manisfests our first mover position as a truly global player in the industry.”
About Harvest One
Harvest One Cannabis Inc. (TSX VENTURE:HVST) controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation license, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
Click here to connect with Harvest One Cannabis Inc. (TSXV:HVT) to receive an Investor Presentation.

Source: www.marketwired.com